Skip to content

We have completed our Covid-19 Phase 2 clinical trial enrollment.

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Contact Us

Contact us with any questions or comments regarding our novel approach to treating infectious, inflammatory, and degenerative diseases with our plasma gelsolin technology platform.

Name

Email

Phone

Organization

Role

Scientist/Academic Media Investor Other

Message

Stay informed of our latest discoveries and news.

EMAIL

GENERAL NEWS/MEDIA

Clinical Trials Arena Award -
Best Covid 19 Response
February 2021

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist

June 4, 2021

April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases

April 8, 2021

March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

March 15, 2021

EVENTS

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

Tweets by BioAegis

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

FOLLOW US

©2020 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use